RE104 Safety and Efficacy Study in Generalized Anxiety Disorder (NCT07489651) | Clinical Trial Compass
Not Yet RecruitingPhase 2
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
64 participantsStarted 2026-04
Plain-language summary
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
Who can participate
Age range18 Years – 74 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Has Generalized Anxiety Disorder as defined by DSM-5-TR
* Is on stable use of antidepressants (i.e., SSRIs or SNRIs) or psychotherapy, or is willing to delay the use until the end of study
* If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
* Is willing and able to comply with the conditions and requirements of the study
Exclusion Criteria:
* Has a significant risk of suicide
* Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
* Has other concurrent psychiatric disorders that is the primary disorder.
* Has other medically significant conditions rendering unsuitability for the study
* Has used or will need to use prohibited medications or therapies
* Has a known sensitivity or intolerance to study intervention or potential rescue medications
What they're measuring
1
RE104 30 mg versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score